Cite
HARVARD Citation
Gambacorti‐Passerini, C. et al. (n.d.). Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up. American journal of hematology. 89 (7), pp. 732-742. [Online].